Micro-dose vaccine approved
Pharmaq's Alpha Ject IPNV-Flavo 0,025, which is manufactured at the company's production facility at Overhalla in Norway, has received provisional marketing authorisation in Chile.
It has been specially developed for the vaccination of salmon at early production stages against Infectious Pancreas Necrosis (IPN) and flavobacteriosis caused by Flavobacterium pshychrophilum.
"In the research and development phase of the Alpha Ject IPNV-Flavo 0,025 vaccine for Chile, we have taken advantage of our experience with the successful Pharmaq micro-dose vaccine technology. At the same time, we feel confident in that this vaccine will be helpful to Chilean fish farmers," says Edel-Anne Norderhus, the company’s Product Development Director.
Chilean freshwater sites have suffered from high mortalities caused by Flavobacterium p. and IPN-virus infection – leading to substantial economic losses accompanied by poor performance of surviving fish. Effective tools against outbreaks of these endemically spread pathogens at early freshwater stages are in great demand from the industry.
"We are sure the introduction of the Alpha Ject IPNV-Flavo 0,025 vaccine will be well received by our customers. Diseases like IPN and flavobacteriosis are commonly known to effect freshwater production in salmonids, not only in Chile. However, in this respect we believe this newest, innovative Pharmaq vaccine will help the industry in establishing effective measures to reduce the impact of these diseases," says Mauricio Toirkens, Commercial Manager at Pharmaq Chile.
